Evidence map›Paper›PMID 41280256›Full record

ArticleClinical case reports2025

Aggressive Disease and Poor Clinical Outcome in CEBPα-Mutated Acute Myeloid Leukemia Patient.

Abdullah Attullah Alshammari, Mohammed O AlSabbagh, Hasan M Alshehri, Azizah F AlSwayyed, Faisal M Alseraye, Abdul Ali Peer-Zada

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Abdullah Attullah AlshammariDepartment of Pathology and Clinical Laboratory Medicine, Hematology, Molecular Pathology Section King Fahad Medical City Riyadh Saudi Arabia.
Mohammed O AlSabbaghDepartment of Pathology and Clinical Laboratory Medicine, Hematology, Molecular Pathology Section King Fahad Medical City Riyadh Saudi Arabia.
Hasan M AlshehriDepartment of Adult Hematology and Bone Marrow Transplantation King Fahad Medical City Riyadh Saudi Arabia.
Azizah F AlSwayyedDepartment of Pathology and Clinical Laboratory Medicine, Hematology, Molecular Pathology Section King Fahad Medical City Riyadh Saudi Arabia.
Faisal M AlserayeDepartment of Pathology and Clinical Laboratory Medicine, Hematology, Molecular Pathology Section King Fahad Medical City Riyadh Saudi Arabia.
Abdul Ali Peer-ZadaDepartment of Pathology and Clinical Laboratory Medicine, Hematology, Molecular Pathology Section King Fahad Medical City Riyadh Saudi Arabia.ORCID https://orcid.org/0000-0002-9172-712X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CCAAT/enhancer binding protein α (C/EBPα) mutations occur in about 4%-11% of AML patients and are typically associated with favorable prognosis. Here we present a case of AML with two distinct CEBPα variants exhibiting an unexpectedly poor clinical outcome despite intensive chemotherapy and molecular remission at an early phase of treatment. Routine diagnostic work-up included in-house morphological assessment, flow cytometry, molecular and cytogenetics testing, and NGS-based CNV testing. A 63-year-old male with a history of trigeminal neuralgia presented to the ER with fever associated with sore throat, cough and spontaneous bruising accompanied by leucocytosis (WBC, 52.4 × 10

Indexed as

AMLCCAAT/enhancer binding protein αcopy‐number‐variantsMRDNGSSTC

Identifiers

PMID41280256
PMCPMC12634877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.